Come contattare il centro
Centro HCP
Con circa 14.100 dipendenti, l'UKE è il terzo datore di lavoro della Città Libera e Anseatica di Amburgo.
Ricerca presso l'UKE
La ricerca è un prerequisito importante per il progresso nella diagnostica e nella terapia. L'accento nella ricerca dell'UKE sono le neuroscienze, la ricerca cardiovascolare, la ricerca sanitaria, l'oncologia, nonché le infezioni e le infiammazioni. Altre potenziali aree dell'UKE sono l'imaging molecolare e la ricerca sulla biologia scheletrica.
Contatti
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
Team
Pr Martin Spitzer
Germania
Dr Johannes Birtel
Germania
Test clinici
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Non-infectious, Intermediate-, Posterior- or Pan-uveitis
Long-Term Non-Interventional Latanoprost Study
European Disease Registry on Retinopathy of Prematurity (ROP)
Early Reperfusion Therapy With Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion
A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)
An Open-label, Active-Controlled, Safety, and Efficacy Study of Oral Baricitinib in Patients From 2 Years to Less Than 18 Years Old With Active Juvenile Idiopathic Arthritis-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis